Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 07 12:42PM ET
14.41
Dollar change
-0.98
Percentage change
-6.39
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y11.44% Shs Outstand Perf Week16.28%
SponsorAdvisor Shares ETF Type Tagsequity Return% 3Y-31.45% Total Holdings27 Perf Month6.72%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM10.65M Perf Quarter20.73%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y45.52%
Index Weighting Commodity Type Tagsmedical Return% SI NAV/sh Perf Year2.17%
Active/Passive Quant Type Tags- Flows% 1M18.07% 52W Range7.14 - 17.00 Perf YTD31.20%
Dividend TTM0.16 (1.13%) ESG Type Tags- Flows% 3M24.26% 52W High-15.26% Beta0.79
Dividend Ex-DateDec 23, 2024 Dividend Type Sector/Theme Flows% YTD18.07% 52W Low101.77% ATR (14)0.58
Expense0.99% Structure Type Region Flows% 1Y RSI (14)63.10 Volatility4.40% 3.30%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume2.59 Prev Close15.39
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume15.05K Price14.41
SMA2010.23% SMA5019.74% SMA20031.86% Trades Volume20,268 Change-6.39%
AdvisorShares Psychedelics ETF seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.